GoHealth’s Q3 2025 results reflect an intentional shift away from volume-driven growth to focus on retention, quality, and strategic flexibility. While revenue dropped significantly year-over-year, the company reinforced its core capabilities to align with changing market dynamics.
Net revenue for Q3 2025 declined to $34.19 million from $118.29 million in Q3 2024.
The company posted a net loss of $165.85 million, primarily due to impairment charges and higher G&A expenses.
Submissions dropped 57% YoY to 72,183, reflecting the company’s strategic pullback.
Adjusted EBITDA was $(47.09) million with a margin of -137.7%.
GoHealth expects continued pressure on top-line growth due to its deliberate pullback, but believes its strategic positioning and retained core capabilities will enable it to capitalize when the market stabilizes.
Analyze how earnings announcements historically affect stock price performance